Altamira TherapeuticsCYTOF
13F holders, Q2 2024 (June 30)4holders +1
2new positions
1sold out
$1.11avg. 13F price*
At the end of Q2 2024, 4 institutions reported holding Altamira Therapeutics Ltd. (CYTOF) in their 13F filings, up 1 from Q1 2024. 2 opened new positions and 1 sold out. The largest holders were UBS Group AG ($2K), Morgan Stanley ($1K) and Group One Trading LLC ($16).
- Company
- Altamira Therapeutics Ltd.
- CUSIP
- G0360L134
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $3K |
| Exits | 1 | $3K |
All 13F filers, Q1 2024 → Q2 2024: 2,644 shares bought and 1,660 shares sold, net +984 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 4 holders
| UBS Group AG | 0.00% | New | 1,711 | $2K |
| Morgan Stanley | 0.00% | New | 933 | $1K |
| Group One Trading LLC | 0.00% | No change | 14 | $16 |
| LRI Investments, LLC | 0.00% | No change | 1 | $1 |
"% of holder's portfolio" is CYTOF's weight in each manager's 13F, not the share of Altamira Therapeutics Ltd. the manager owns.